PsyMed Ventures

General Partners and co-founders Matias Serebrinsky and Greg Kubin lead investment decisions. Serebrinsky brings experience running Nvidia Inception in North America and co-founding CookUnity, while Kubin previously co-founded a SaaS platform and personally invested in over 20 mental health companies. Dina Burkitbayeva, the third co-founder, focuses on portfolio operations as CEO of Freedom Biosciences. The firm's investment committee is supplemented by venture partners with technical neuroscience background.

PsyMed sources through a combination of academic neuroscience networks, operator referrals from its podcast 'Business Trip', and relationships with incubators and accelerators in the neurotech space. Venture Partner Tim Gardner, a founding Neuralink member, provides direct access to brain-computer interface and bioengineering talent. The firm's public content and newsletter platform serve as an inbound magnet for founders operating at the intersection of AI, digital health, and psychiatry.

PsyMed concentrates on neuropsychiatry, neurodegeneration, and mental health broadly. This includes RNAi medicines (Aerska), non-hallucinogenic psychedelics (Delix Therapeutics), bioelectronic interventions (Motif Neurotech), and digital therapeutics for ADHD (Neurode). The firm also invests in peripheral modalities that affect brain health, such as metabolic psychiatry and holistic medicine.

Business Trip is co-hosted by general partners Matias Serebrinsky and Greg Kubin. The podcast explores the future of mental health and wellness and operates as both a public education platform and a deal-flow engine. It reinforces PsyMed's positioning as a thematic investor by surfacing emerging research, products, and founders to a specialist audience.